56
15.
Blander JM, Medzhitov R. Toll-de-
pendent selection of microbial an-
tigens for presentation by dendritic
cells. Nature 2006; 440:808 – 812.
16.
Crespo- Lessman A, Juarez- Rubio
C, Plaza Moral V. Papel de los recep-
tores Toll- like en las enfermedades
respiratorias. Arch Bronconeumol
2010;46(3):135-142
17.
Moingeon P, Lombardi V, Saint-Lu N
et al. Adyuvants and vector system
for allergy vaccines. Immunol Aller-
gy Clin North Am 2011; 31:407-419
18. Simons FE, ShikishimaY, Van Nest G,
et al. Selective immune redirection in
humans with ragweed allergy by in-
jecting Amb a 1 linked to immunos-
timu- latory DNA. J Allergy Clin Im-
munol 2004; 113:1144 – 1151.
19.
Tulic MK, Fiset PO, Christodou-
lopoulos P, et al. Amb a 1-immu-
nostimulatory
oligodeoxynucle-
otide conjugate immunotherapy
decreases the nasal inflammatory
response. J Allergy Clin Immunol
2004; 113:235–241.
20.
Creticos PS, Schroeder JT, Hamilton
RG, et al. Immunotherapy with a
ragweed-Toll-like receptor 9 agonist
vaccine for allergic rhinitis. N Engl J
Med 2006; 355:1445–1455.
21.
BusseW, Gross G, Korenblat P, et al.
Phase 2/3 study of the novel vaccine
Amb a 1 immunostimulatory oligo-
deoxyribonucleotide conjugate AIC
in ragweed-allergic adults. J Allergy
Clin Immunol 2006; 117 (2 Suppl.):
88–89.
22.
Johansen P, senti G, martinez
Gomez JM, Storni T, Von Benst BR,
Wüthrich B, Bot A, Kündog TM. Toll
like recetor ligands as adjuvant in
allergen- specific immunotherapy.
Clin Exp Allergy 2005; 35:1591-1598
23.
Puggioni F, Durham SR, Francis JN.
Monophosphoryl lipid A (MPL) pro-
motes allergen-induced immune
3 Shamji MH, DurhamSR. Mechanism
of immnunotherapy to aerollergens.
Clin Exp Allergy 2011;41:1235-46
4.
Akdis CA, Akdis M. Mechanism of
allergen specific immunotherapy. J
Allergy Clin Immunol 2011;127:18-
27
5.
Akdis CA, blaser K. Bypassing IgE
targetingT cells for the especific im-
munotherapy of allergy. Tends Im-
munol 2001;22: 175-8
6.
Valenta R, Niederberger V. Recom-
binant allergens for immunother-
apy. J Allergy Clin Inmunol 2007;
119:826-30
7.
ChapmanM,WünschmannS, Pames
A. Proteasas as aTH2 adyuant. Curr
allergy Asthma Rep. 2007;7:363-7
8.
Trived B, Valerio C, Slater JE. Endo-
toxin content of standarized aller-
gens vaccines. J Allergy Clin Immu-
nol 2003;111:777-83
9.
Martinez FD. The coming-of-age
of the higiene hypothesis. Respir
Res2001;2:129-32
10.
Weiss ST. Eat dirt- the hygiene hy-
pothesis and allergy diseases. N
Engl J med 2002; 347:930-1
11.
Novak N, Allam JP. Mucosal dendrit-
ic cells in allergy and immunother-
apy.Allergy 2011; 66 (Suppl. 95):22
– 24
12.
Barton GM, Medzhitov R. Toll-like
receptors and their ligands. Curr
Top
Microbiol Immunol 2002;
270:81 – 92.
13.
Novak N, Koch S, Allam JP, Bieber
T. Dendritic cells: bridging innate
and
adaptive immunity in atopic
dermatitis. J Allergy Clin Immunol
2010; 125:50–
59.
14.
Kelsall BL. A focus on dendritic cells
and macrophages as key regulators
of mucosal immunity. Mucosal Im-
munol 2008; 1:423 – 424
Nuevas modalidades de inmunoterapia en niños
